Key regulators of sensitivity to immunomodulatory drugs in cancer treatment
Abstract Immunomodulatory drugs (IMiDs) include thalidomide, lenalidomide, and pomalidomide, which have shown significant efficacy in the treatment of multiple myeloma (MM), myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)) and other hematological malignancies. IMiDs hijack the...
Saved in:
Main Authors: | Shichao Wang (Author), Zhiyue Li (Author), Shaobing Gao (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2021-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Novel immunomodulatory drugs and neo-substrates
by: Shaobing Gao, et al.
Published: (2020) -
Immunomodulatory and Antioxidant Drugs in Glaucoma Treatment
by: Francesco Buonfiglio, et al.
Published: (2023) -
Immunomodulatory Effects of Drugs for Treatment of Immune-Related Diseases
by: Azzam A. Maghazachi
Published: (2017) -
Alcohol: Immunomodulatory effects and cancer
by: Juan C. Molina, et al.
Published: (2023) -
Anticancer peptides as novel immunomodulatory therapeutic candidates for cancer treatment
by: Apurva Sood, et al.
Published: (2024)